Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced its abstract was accepted for a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, January 8-10, 2026.
The poster, titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation," is Abstract 693 and will be presented by Robert S. Schwartz, MD, Chief Medical Officer. Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Presentation times: January 9, 2026, 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST.
Positive
- None.
Negative
- None.
News Market Reaction – AMIX
In the Dec 18 session, AMIX gained 4.59%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Strategy update | Positive | +10.2% | CEO Corner segment outlining IP protection and expansion beyond pancreatic cancer. |
| Nov 18 | Private placement | Negative | -17.4% | At‑the‑market priced $5.0M private placement with shares and Series C warrants. |
| Nov 17 | Clinical data update | Positive | +58.2% | Post‑hoc PoC subgroup analysis showing sustained quality‑of‑life improvements. |
| Oct 24 | Conference presentations | Positive | +0.0% | TCT conference podium talks on first‑in‑human PoC pancreatic cancer pain study. |
| Oct 16 | Investor conference | Positive | -1.8% | Maxim Growth Summit appearance focused on nerve‑sensing and ablation platform. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often produced price reactions aligned with the apparent sentiment: positive clinical or strategy updates saw gains, while financing actions weighed on shares, with conference/investor events sometimes seeing muted or negative moves.
Over the past few months, AMIX has highlighted its nerve-targeted platform across multiple channels, from the Oct 25–28, 2025 TCT conference podium presentations to a Nov 26, 2025 CEO Corner on strategic growth. Positive pancreatic cancer proof-of-concept data on Nov 17, 2025 corresponded with a strong gain, while the $5.0 million private placement on Nov 18, 2025 coincided with a sharp decline. Today’s ASCO GI poster selection extends this pattern of clinical and visibility milestones following earlier PoC results.
Key Terms
pancreatic adenocarcinoma medical
denervation medical
transvascular medical
RF energy-based ablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA.
Details of the poster presentation are as follows:
Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation
Abstract Number: 693
Presenter: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date and Time: January 9, 2026 from 11:30 AM-1:00 PM and 5:00 PM-6:00 PM PST
About ASCO
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
